Agios Pharmaceuticals amends bylaws to update proxy rules and meeting procedures

AGIOS PHARMACEUTICALS, INC.

Revised procedural mechanics for stockholder nominations under universal proxy rules.
Requires additional background info and representations from proposing stockholders.
Clarifies that failure to comply with Rule 14a-19 may result in disregarding nominations.
Eliminates requirement to make stockholder list available during meeting.
Adds emergency provisions limiting officer/director liability to willful misconduct.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

AGIOS PHARMACEUTICALS, INC.: Amended and restated the bylaws to update procedural mechanics and disclosure requirements for stockholder nominations and proposals, among other changes (effective 2023-03-02).

Change: bylaw amendment
Effective: 2023-03-02

Exact text from the filing

On March 2, 2023, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”) approved an amendment and restatement of the Company’s Second Amended and Restated By-Laws (as so amended and restated, the “Third Amended and Restated By-Laws”), effective immediately.

View on SEC.gov

11 governance changes filed in the last 30 days. Browse all governance changes →

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-060031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.